Glucagon Resistance in Patients With NAFLD

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 5, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

August 18, 2022

Conditions
Non-Alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisGlucose Metabolism Disorders
Interventions
OTHER

glucagon

Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.

Trial Locations (1)

8200

Aarhus University Hospital, Aarhus

All Listed Sponsors
collaborator

Danish Council for Independent Research

OTHER

lead

University of Aarhus

OTHER

NCT04042142 - Glucagon Resistance in Patients With NAFLD | Biotech Hunter | Biotech Hunter